List of Studies ( Metabolite:Deoxyamidinoproclavaminic acid)
Study_id | Analysis_id | Study_title | Source | Species | Disease | Institute | Units(range) |
---|---|---|---|---|---|---|---|
ST002016 | AN003284 | Metabolomics of COVID patients | Blood | Human | COVID-19 | University of Virginia | intensity |
ST002775 | AN004517 | Zebrafish Retina Regeneration Metabolomics - 3 Days Post Crush | Eye tissue | Zebrafish | Eye disease | University of Miami | Normalized Concentrations |
ST002444 | AN003981 | Zebrafish Optic Nerve Regeneration Metabolomics - 3 Days Post Crush | Eye tissue | Zebrafish | Eye disease | University of Miami | normalized peak areas |
ST002306 | AN003768 | Metabolomics profiling of full extracts of bacterial culture supernatants. | Bacterial cells | Bacillus megaterium | Myalgic encephalomyelitis/chronic fatigue syndrome | University of Connecticut | peak area |
ST002306 | AN003768 | Metabolomics profiling of full extracts of bacterial culture supernatants. | Bacterial cells | Enterococcus faecium | Myalgic encephalomyelitis/chronic fatigue syndrome | University of Connecticut | peak area |
ST000291 | AN000465 | LC-MS Based Approaches to Investigate Metabolomic Differences in the Urine of Young Women after Drinking Cranberry Juice or Apple Juice | Urine | Human | University of Florida | Peak area | |
ST002792 | AN004542 | Chemoproteomics validates selective targeting of Plasmodium M1 alanyl aminopeptidase as a cross-species strategy to treat malaria | Blood | Plasmodium falciparum | Malaria | Monash University | peak height |
ST003024 | AN004958 | Identifying and mathematically modeling the time-course of extracellular metabolic markers associated with resistance to ceftolozane/tazobactam in Pseudomonas aeruginosa - Part 1 | Bacterial cells | Bacteria | Monash Institute of Pharmaceutical Sciences | peak height | |
ST003036 | AN004978 | Identifying and mathematically modeling the time-course of extracellular metabolic markers associated with resistance to ceftolozane/tazobactam in Pseudomonas aeruginosa - Part 2 | Bacterial cells | Pseudomonas aeruginosa | Bacterial infection | Monash Institute of Pharmaceutical Sciences | peak height |
ST003053 | AN005007 | Providing insight into the mechanism of action of Cationic Lipidated Oligomers (CLOs) using metabolomics | Bacterial cells | Staphylococcus aureus | Bacterial infection | Monash University | peak height |
ST003144 | AN005159 | On-target, dual aminopeptidase inhibition provides cross-species antimalarial activity | Blood | Plasmodium falciparum | Malaria | Monash University | peak height |
ST003521 | AN005782 | Metabolic Profiling Unveils Enhanced Antibacterial Synergy of Polymyxin B and Teixobactin against Multi-Drug Resistant Acinetobacter baumannii | Bacterial cells | Acinetobacter baumannii | Bacterial infection | Monash University | peak height |
ST003521 | AN005783 | Metabolic Profiling Unveils Enhanced Antibacterial Synergy of Polymyxin B and Teixobactin against Multi-Drug Resistant Acinetobacter baumannii | Bacterial cells | Acinetobacter baumannii | Bacterial infection | Monash University | peak height |
ST002094 | AN003420 | Commensal intestinal microbiota regulates host luminal proteolytic activity and intestinal barrier integrity through β-glucuronidase activity (Part 1) | Feces | Human | Irritable bowel syndrome | Mayo Clinic | raw intensity |
ST002108 | AN003448 | Genetic and chemical validation of Plasmodium falciparum aminopeptidase PfA-M17 as a drug target in the hemoglobin digestion pathway (Part 3) | Blood | Plasmodium falciparum | Malaria | Monash University | relative intensity |